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Background: Our aim was to explore the therapeutic effects of peripheral blood-derived endothelial progenitor
cells (PB-EPC) in cardiac ischemia-reperfusion infarction models in rats and in in vitro culture systems.
Methods: Rat models of ischemia reperfusion and myocardial infarction were developed using male,
Sprague–Dawley rats. Cardiomyocyte and endothelial cell cultures were also established. Therapeutic effects of
PB-EPCs were examined in vivo and in vitro in both models. Rats underwent either cardiac ischemia-reperfusion
(n = 40) or infarction (n = 56) surgeries and were transplanted with genetically modified EPCs. Treatment efficacy in
the ischemia-reperfusion group was measured by infarct size, myocardial contraction velocity, and myeloperoxidase
activity after transplantation. Cardiomyocyte survival and endothelial cell apoptosis were investigated in vitro.
Vascular growth-associated protein expression and cardiac function were evaluated in the myocardial infarction
group by western blot and echocardiography, respectively.
Results: Infarct size and myeloperoxidase activity were significantly decreased in the ischemia-reperfusion group,
whereas myocardial contractility was significantly increased in the EPC and Tβ4 groups compared with that in the
control group. In contrast, no differences were found between EPC + shRNA Tβ4 and control groups. Rates of
cardiomyocyte survival and endothelial cell apoptosis were significantly higher and lower, respectively, in the EPC
and Tβ4 groups than in the control group, whereas no differences were found between the EPC + shRNA Tβ4 and
control group. Four weeks after myocardial infarction, cardiac function was significantly better in the EPC group
than in the control group. Expressions of PDGF, VEGF, and Flk-1 were significantly higher in EPC group than in
control group.
Conclusions: Study findings suggest that PB-EPCs are able to protect cardiomyocytes from ischemia-reperfusion or
infarction-induced damage via a Tβ4-mediated mechanism. EPCs may also provide protection through increased
expression of proteins involved in mediating vascular growth. Autologous peripheral-blood-derived EPCs are readily
available for efficient therapeutic use without the concerns of graft rejection.
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Cardiovascular disease is one of the leading causes of
death in developed and developing countries. In 2008,
there were 17 million deaths due to cardiovascular dis-
ease worldwide (including 7.3 million due to coronary
heart disease), accounting for 30% of all global deaths
[1]. Revascularization is the goal of current clinical ther-
apy after myocardial infarction. Clinically successful re-
vascularization urgently increases blood flow to the
ischemic area to salvage cells while standard therapy is
being established. Reperfusion is necessary for tissue sur-
vival, but may itself result in tissue damage. The patho-
physiological process of ischemia-reperfusion injury in
prolonged myocardial ischemia results in cardiomyocyte
loss, microcirculatory disturbances and post-ischemic in-
flammation [2]. Although cardiomyocyte regeneration
takes place throughout human life at about 1% per year
[3], cardiomyocytes only have a limited capacity to regen-
erate. Most types of heart disease, especially prolonged is-
chemia and heart failure, are characterized by a loss of
cardiomyocytes. Notably, after myocardial infarction,
cardiomyocytes are incapable of sufficient regeneration
to correct losses. This can lead to the development of
chronic heart failure among survivors of infarction. It
follows then, that therapeutic strategies that stimulate
cardiomyocyte renewal are a logical target for treating
cardiac pathologies [3].
Transplantation of various types of cells have been in-
vestigated as possible treatment for cardiac dysfunction
after myocardial infarction [4-6], including human umbil-
ical vein endothelial cells [4], microspheres and fibroblasts
[5], and progenitor cell populations [6]. Circulating endo-
thelial progenitor cells (EPCs) are derived from peripheral
mononuclear cells and appear to play an important
cardioprotective role. These cells have proliferative poten-
tial and can differentiate into mature endothelial cells.
Under normal circumstances, EPCs account for approxi-
mately 0.1% of peripheral blood cells. As such, EPCs con-
stitute a circulating pool of cells that counteract ongoing
risk factor-induced endothelial cell injury and replace dys-
functional endothelium [7]. When required for vascular
repair/angiogenesis or in cases of vascular stress, EPCs
enter the peripheral blood and migrate to areas of endo-
thelial damage to begin the reparative process [8]. How-
ever, after acute coronary occlusion, the supply of
circulating EPCs is insufficient for neovascularization of
ischemic myocardial tissues and vascular repair.
An accumulation of cardiovascular risk factors and
the presence of coronary or peripheral atherosclerosis
have been found to be associated with dysfunction and
reduced numbers of EPCs [9-11]. Moreover, a low EPC
concentration has been shown to be an independent
risk factor of future cardiovascular events [7,12]. Not-
ably, recent evidence suggests that EPCs may providecardioprotection against acute ischemia-reperfusion
injury [7,9-12].
Thymosin β4 (Tβ4) contains 43 amino acids and is
abundantly expressed in EPCs [13]. Tβ4 promotes endo-
thelial cell differentiation, tubule formation, migration,
angiogenesis in vitro, and mediates adult cardiac repair
[14]. Of particular note, the findings from a study in-
corporating in vivo and in vitro animal experiments sug-
gest that the short-term cardioprotective effects of
regional application of EPCs may be partially attributable
to Tβ4 [15]. We aimed to confirm the previously
reported findings regarding the importance of Tβ4 in
mediating the effects of EPCs. Our hypothesis was that
we could use EPCs isolated from peripheral blood to
treat cardiomyocyte infarction. The benefits for using
these cells are that they are readily available for use in
treatment after purification and amplification, and that
concerns about graft rejection are eliminated since the
process is autotransplantation. Therefore, the purpose of
this study was to explore the therapeutic effects of periph-
eral blood-derived endothelial progenitor cells (PB-EPCs)
in rat models of cardiac ischemia-reperfusion and infarc-
tion and in in vitro culture systems and to further investi-




Sprague Dawley rats were purchased from Tongji Medical
College (Wuhan, China). A total of 40 male rats were in-
cluded in the ischemia-reperfusion model; 56 male rats
were included in the myocardial infarction model; 16 male
rats were used to establish cardiomyocyte cultures; and 14
neonatal rats were used to establish endothelial cell cul-
tures. This study was performed in accordance with the
instructions outlined in the Guidelines for the Care and
Use of Laboratory Animals (US National Institutes of
Health) and was approved by the Ethics Committee of
Tongji Medical College, Huazhong University of Science
and Technology.
Isolation and identification of EPCs
EPCs were isolated and identified as previously de-
scribed [16]. Briefly, peripheral blood obtained from
rats was subjected to density gradient centrifugation
to isolate EPCs. The EPCs were further processed
by flow cytometry for identification and purification.
Please see Zhao et al. for a detailed description of the
methods [16].
RNA interference
Tβ4 short hairpin RNA (shRNA) and scrambled (SC)
shRNA were prepared using a commercially available kit
(pSuperior.retro, Oligoengine Seattle, WA) as previously
Chang et al. Journal of Cardiothoracic Surgery 2013, 8:33 Page 3 of 10
http://www.cardiothoracicsurgery.org/content/8/1/33described [15] and EPCs were transfected with using
Lipofectamine 2000 reagent (Life Technologies, Carlsbad,
CA). Transfection efficiency was confirmed by real-time
polymerase chain reaction as previously described [15].
Rat ischemia-reperfusion model
Ischemia-reperfusion was induced in 40 male Sprague–
Dawley rats (weight: 230 to 350 g; aged: 7 to10 weeks)
via the following procedure. Rats were anesthetized with
ketamine (100 mg/kg) and xylazine (10 mg/kg). The chest
was opened by middle thoracotomy. After pericardiotomy,
a 4–0 black silk ligature was placed under the left anterior
descending (LAD) coronary artery, and the ends of the tie
were threaded through a small vinyl tube to form a snare
to facilitate reversible LAD coronary artery occlusion for
40 min. Myocardial ischemia was confirmed by the ap-
pearance of regional epicardial cyanosis over the myocar-
dial surface and by arrhythmia. After 35 min of ischemia,
rats received intramyocardial injection into the infarct
and peri-infarct regions of the heart. Reperfusion was
established by loosening the snare. Successful reperfu-
sion was confirmed by the disappearance of epicardial
cyanosis, epicardial hyperemia, and arrhythmia [17].
Muscle and skin incisions were closed using 3–0 silk ab-
sorbable suture. Rats received postoperative buprenorphine
and cefazolin (0.1 mg/kg and 40 mg/kg, respectively) via
subcutaneous injection for 5 days. Operation site spray and
topical antibiotic powder was applied to the wound to pre-
vent infection. Intraperitoneal injections of the immuno-
suppressive agent cyclosporine were given to all rats daily
for 4 days before cell transplantation and for 6 weeks after
transplantation [18]. Infarct size, MPO assay and assess-
ment of hemodynamics and myocardial contractility were
assessed as described below.
Myeloperoxidase assay
At 24 hours after reperfusion, rats were anesthetized as
described above. The chest was then opened at the fourth
intercostal space and the heart was removed by applying
gentle pressure to either side of the incision. The LAD
coronary artery was permanently occluded and 2 mL of
Evans blue (1% in saline) was infused via the jugular vein
to determine the area at risk (AAR), non-ischemic area
and infarct size. The AAR, non-ischemic area and infarct
region were homogenized in buffer containing 20 mM so-
dium phosphate buffer (pH 4.7), 0.015 M EDTA, and 0.1M
sodium chloride before centrifugation at 10,000 rpm for 15
minutes at 4°C. MPO activity was defined as the quantity of
enzyme degrading 1 μmol of peroxide per minute at 25°C
and is expressed as units per gram of weight [19].
Hemodynamics and myocardial contractility
At 72 hours after reperfusion, rats were anesthetized as
described above and the right common carotid arterywas cannulated with a 2-Fr Millar catheter. The catheter
was advanced into the left ventricle (LV) to measure the
heart rate (HR), left ventricular systolic pressure (LVSP),
left ventricular end diastolic pressure (LVEDP), the in-
crease in the peak rate of intraventricular pressure in-
crease (+dP/dtmax), and the decrease in the peak rate of
intraventricular pressure (−dP/dtmax) [20].
Rat myocardial infarction model
Myocardial infarction was induced in 56 male rats
(weight: 230 to 350 g; age: 7 to 10 weeks) randomly
divided into an EPC treatment group (n = 28; 150 μL
containing 5 × 106 cells) and a control group (n = 28).
Rats were anesthetized by intraperitoneal injection of
ketamine (70 to 80 mg/kg). The analgesic buprenorphine
was given preoperatively (10 to 20 μg/kg body weight,
intraperitoneal). The rats were connected to a respirator
via tracheotomy. The right external jugular vein was
cannulated for systemic intravenous administration of
treatment. A left-sided thoracotomy was performed by
cutting the fifth and sixth ribs. The pericardium was
opened, and the heart exteriorized with a cardiac holder
consisting of a plastic loop (1.5 × 2 cm). The LAD was
localized 1–2 mm below the junction of the pulmonary
conus and the left atrial appendage [21], and was ligated
from the left border of the pulmonary conus to the right
border of the left atrial appendage using 5–0 silk suture.
The heart was moved from its exteriorized position to
its normal position in the chest cavity. Presutured loops
of 4–0 silk were used to close the chest wall [21]. Post-
operative care and immunosuppressive treatment was
done as per the ischemia-reperfusion model except that
immunosuppressive treatment was continued for up to 4
weeks as necessary. Cardiac function was assessed as
shown below.
Cardiac function
Echocardiograms to assess systolic function were performed
using M-mode and two-dimensional measurements. Rats
were anesthetized with 5% isoflurane (3.5 L/m O2 for 30 s)
followed by 2% isoflurane and O2 for an average of 10 to
15 min. Echocardiographic measurements were made 4 to
7 mins after the induction of anesthesia to allow for
resolution of any transient anesthesia-related cardiac
depression. Measurements comprised the average of six
selected cardiac cycles from at least two separate scans
performed in a random-blind fashion with papillary
muscles used as a reference point for consistency in
scan levels. End diastole was defined as the maximal left
ventricle diastolic dimension and end systole was de-
fined as the peak posterior wall motion. Single outliers
in each group were omitted for statistical analysis.
Fractional shortening, (FS%), a surrogate of systolic
function, was calculated from LV dimensions as follows:
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dimensions at end diastole and end systole, respectively.
The ejection fraction (EF) was calculated from two-
dimensional images.
Determination of area at risk and infarct size
After analyzing hemodynamic function, the LAD
coronary artery was relegated to its original position
and treated as described above to identify myocardial
AAR. The atria, right ventricles, and major vessels
were removed. The LV was then sliced transversely
into 2 mm thick slices. To distinguish between ische-
mic and non-ischemic tissue, the slices were incubated
in 1% triphenyltetrazolium chloride at 37°C, pH 7.4 for
20 min. AAR pieces were separated according to the
extent of staining and weighed to determine the infarct
size as a percentage of the weight of the AAR. AAR
was expressed as a percentage of the LV as previously
described [17].
Western-blot analysis
Sternotomy was performed on rats (n = 6 per group) 24
hours after myocardial infarction. Heart tissue was
harvested from non-infarct regions of the heart. Dena-
tured cell lysates (50 μg) were resolved on a 10% sodium
dodecylsulfate polyacrylamide gel and then transferred
to nitrocellulose membranes. The membranes were
blocked with 5% non-fat dry milk in Tris buffered saline
for 2 hours at room temperature. Thereafter, membranes
were incubated with primary antibodies (1:2000) against
fibroblast growth factor-17 (FGF-17), fibroblast growth
factor receptor-2 (FGFR-2), β-Catenin, vascular endothe-
lial growth factor (VEGF), fetal liver kinase-1 (Flk-1),
Tbx-18, and platelet-derived growth factor (PDGF)
(Santa Cruz Biotechnology, Santa Cruz, CA) at 4°C over-
night. After being washed three times for 10 min each in
TBS–0.05% Tween 20, the membranes were incubated
with horseradish peroxidase conjugated secondary anti-
body (1:3000) for 2 hours at room temperature. Specific
bands were detected using the Pierce ECL detection sys-
tem (Thermo-Fischer Scientific, Beijing, China). Band
intensities were quantified with NIH Image Version 1.61.
GAPDH was used as an internal control.
Cardiomyocyte and endothelial cell cultures
For culture of cardiomyocytes, 16 rats were sacrificed
(intraperitoneal sodium pentobarbital: 120 mg/kg) for
endothelial cell culture and hearts were quickly excised
via midline thoracotomy. Ventricular cardiac muscle
cells were isolated and plated in medium 199 with 4%
fetal calf serum on glass coverslips as previously de-
scribed [13]. Two to three coverslips were used for each
isolation. Approximately 4 hours after plating, the cells
were washed with medium 199 and then exposed to 4hours of hypoxia and then 1 hour of reoxygenation. The
EPCs were placed in a transwell/permeable insert in the
well before hypoxia. At the end of the experiment, Try-
pan blue was added for 2 minutes, and 5 microscopic
fields were photographed to quantify cell survival.
For culture of endothelial cells, 14 2- to 3-day-old neo-
natal rats (preferred for superior viability of isolated cells)
were sacrificed by cervical dislocation under anesthesia
using pentobarbital (40 mg/kg, intraperitoneal). Coronary
endothelial cells were harvested from rat hearts by colla-
genase and trypsin digestion. After seeding for 1 hour
on collagen-coated dishes, nonadherent cells were re-
moved and incubated with DMEM with 10% PBS as
previously described [15]. EPCs, with or without Tβ4
shRNA transfection, were added to the cultures. Cor-
onary endothelial cells were exposed to 18 hours of
hypoxia, followed by 4 hours of reoxygenation and
then fixed with 4% paraformaldehyde. The extent of
apoptosis was determined using a commercial terminal
deoxynucleotidyl transferase–mediated dUTP nick-end
labeling staining kit.
Statistical analysis
Data are presented as mean with standard deviation.
Comparisons were performed using ANOVA with post-
hoc comparison adjusted using the Bonferroni method.
Data were analyzed using SPSS 15.0 statistics software
(SPSS Inc, Chicago, IL). P values < 0.05 were considered
to be statistically significant.
Results
Ischemia-reperfusion model
Infarct size and AAR
The impact of Tβ4/EPCs on infarct size and AAR is
summarized in Figure 1. Three days after injection, in-
farct size was significantly reduced in the Tβ4 (38 ± 3%)
and EPC (32 ± 3%) groups compared with that in the
control group (60 ± 3%; Figure 1A). Intramyocardial
injection of EPCs with SC shRNA resulted in similar
cardioprotective effects to EPCs-alone group. Knock-
down of Tβ4 mRNA by Tβ4 shRNA reversed the
EPC-induced decrease in infarct size compared with
that in the EPCs group (P < 0.05). No significant dif-
ferences were found in infarct size between the EPC
group and the EPCs + SC shRNA group. The exten-
sion of the infarct at risk (AAR/left ventricle [LV]
area) did not differ significantly between groups
(Figure 1B).
Hemodynamics and myocardial contractility
The impact of Tβ4/EPCs on myocardial contractility is
summarized in Figures 2A and 2B. Both -dP/dtmax and +
dP/dtmax were significantly increased in the EPCs and
Tβ4 groups compared with those in the control group
Figure 1 The effect of EPC and Tβ4 in a myocardiac infarction model. Infarct size (A) and area at risk (AAR: B) in rats 72 hours after ligating
the LAD coronary artery. Rats were treated with: endothelial progenitor cells (EPCs) (150 μL, 5 × 106 cells per rat); EPCs transfected with Tβ4 short
hairpin RNA (shRNA) (150 μL, 5 × 106 cells per rat); EPCs transfected with scrambled (SC) shRNA (150 μL, 5 × 106 cells per rat); or 6 mg Tβ4.
Control rats were untreated. *P < 0.05 compared with the control group; †P < 0.05 compared with the Tβ4 group; ‡P < 0.05 compared with the
EPC group; § P < 0.05 compared with the EPC + Tβ4 shRNA group. Data are presented as mean ± standard deviation (n = 8 per group).
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of EPCs for both variables (EPC vs. EPCs + Tβ4 shRNA,
P < 0.05).
Myeloperoxidase activity
The impact of Tβ4/EPCs on MPO activity in non-
ischemic, AAR, and infarct tissue is summarized inFigure 2 Measurement of cardiac functions and myeloperoxidase act
(+dP/dtmax: A), decrease in the peak rate of intraventricular pressure (−dP/
C) in rats 24 hours after ischemia-reperfusion injury. Rats were treated with
transfected with Tβ4 short hairpin RNA (shRNA) (150 μL, 5 × 106 cells per ra
per rat); or 6 mg Tβ4. Control rats were untreated. *P < 0.05 compared with
compared with the EPC group; §P < 0.05 compared with the EPCs + SC shR
per group).Figure 2C. MPO activity in AAR and infarct tissue was
significantly reduced in the Tβ4 group compared with
that in the control group (P < 0.05). Similar reductions
were seen in the EPCs + SC shRNA group (P < 0.05) and
the EPC group (P < 0.05). Notably, Tβ4 shRNA blocked
the inhibitory effect of EPCs on MPO activity (EPCs +
Tβ4 shRNA vs. EPCs + SC shRNA, P < 0.05).ivities. Increase in the peak rate of intraventricular pressure increase
dtmax: B) in rats 72 hours, and cardiac myeloperoxidase activity (MPO:
: endothelial progenitor cells (EPCs) (150 μL, 5 × 106 cells per rat); EPCs
t); EPCs transfected with scrambled (SC) shRNA (150 μL, 5 × 106 cells
the control group; †P < 0.05 compared with the Tβ4 group; ‡P < 0.05
NA group. Data are presented as mean ± standard deviation (n = 8
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The impact of Tβ4/EPCs on cardiomyocyte survival and
endothelial cell apoptosis after hypoxia-reoxygenation is
summarized in Figure 3. Cardiomyocyte survival was sig-
nificantly increased in the Tβ4 and EPCs + SC shRNA
groups compared with that in the control group (both P <
0.05; Figure 3A). Tβ4 shRNA blocked the protective effect
of EPCs on cardiomyocyte survival (EPCs + Tβ4 shRNA
vs EPCs + SC shRNA, P < 0.05). Endothelial cell apoptosis
was significantly decreased in the Tβ4 and EPCs + SC
shRNA groups compared with that in the control
group (both P < 0.05; Figure 3B). Tβ4 shRNA blocked the
protective effect of EPCs on endothelial cell apoptosis
(EPCs + Tβ4 shRNA vs EPCs + SC shRNA, P < 0.05).
Myocardial infarction model
Cardiac function
The impact of EPCs on cardiac function at 2 and 4
weeks after myocardial infarction is summarized in
Table 1. At both 2 and 4 weeks after infarction, the end
diastolic and end systolic dimensions were significantly
lower in the EPC group compared with those dimen-
sions in the control group (P < 0.05). In contrast, frac-
tional shortening and ejection fraction were significantly
higher in the EPC group compared with those in the
control group at the given weeks (P < 0.05).
Western blot analysis
The impact of EPCs on the expression of vascular
growth-associated proteins in heart tissue 24 hours after
myocardial infarction is summarized in Figure 4. Expres-
sions of PDGF, VEGF, and Flk-1 were significantly higher
in the EPC group compared with those in the control
group (all P < 0.05). No other significant between-group
differences were found in protein expression levels.Figure 3 Measuring EPC function in an in vitro assay. Cardiomyocyte s
reoxygenation (18 h-4 h) ischemia-reperfusion. Cells were incubated with: e
hairpin RNA (shRNA); EPCs transfected with scrambled (SC) shRNA in transw
were not treated beside hypoxia-reoxygenation *P < 0.05 compared with th
compared with the EPC group; §P < 0.05 compared with the EPCs + SC shR
per group).Discussion
To investigate the effects of treatment with peripherally-
derived EPCs on myocardial infarction in vitro, we evaluated
whether PB-EPCs treatment might increase myocardial re-
pair after acute coronary occlusion in two rat models. PB-
EPCs were shown to reduce infarct size, decrease ischemia/
reperfusion injury, attenuate inflammation, and improve
post-infarction cardiac function.
PB-EPCs reduced infarct size and decreased ischemia-
reperfusion injury
In the present study, Tβ4-transfected PB-EPCs reduced
infarct size and increased regional myocardial contrac-
tion reserve in an LAD occlusion model. The impact of
Tβ4 or EPCs on infarct size was assessed as the ratio of
nonviable myocardium to the AAR, revealing that trans-
plantation of PB-EPCs decreased ischemia/reperfusion
injury in a rat model. The ability of Tβ4 or EPCs to pre-
vent cell death within 72 hours after coronary ligation
likely leads to the decreased infarct size and explains the
improved regional myocardial contraction reserve ob-
served in rats in this study. Incubation of PB-EPCs with
Tβ4 resulted in an increase in cell viability and prolifera-
tion and had an inhibitory effect on EPCs apoptosis. Our
findings are consistent with those of Bock-Marquette
et al. (2004) in which Tβ4 stimulated migration of
cardiomyocytes and endothelial cells, showing enhanced
survival of embryonic and postnatal cardiomyocytes
cultured with Tβ4 [22]. Investigators explained that the
LIM proteins ILK and PINCH, which are both essential
in cell migration and survival, form a complex with Tβ4
that results in phosphorylation of Akt; in mice, this
activity enhanced early myocyte survival and improved
cardiac function, which may point to activation of Akt
as the dominant mechanism by which Tβ4 promotes cellurvival (A) and endothelial cell apoptosis (B) after exposure to hypoxia-
ndothelial progenitor cells (EPCs); EPCs transfected with Tβ4 short
ell plate; Tβ4 were added directly into culturing well. Control cells
e control group; †P < 0.05 compared with the Tβ4 group; ‡P < 0.05
NA group. Data are presented as mean ± standard deviation (n = 6
Table 1 Measures of cardiac function in rats with myocardial infarction who received treatment with endothelial
progenitor cells
Time Groups EDD ESD FS EF
Week 2 Control (n = 28) 7.01 ± 0.27 4.11 ± 0.17 46.41 ± 2.25 31.67 ± 2.94
EPCs (n = 28) 6.01 ± 0.19* 3.09 ± 0.18* 60.51 ± 2.17* 66.18 ± 2.16*
Week 4 Control (n = 28) 6.57 ± 0.28 3.66 ± 0.34 43.49 ± 3.07 35.37 ± 2.39
EPCs (n = 28) 5.69 ± 0.24* 2.64 ± 0.33* 56.48 ± 2.68* 68.39 ± 3.89*
EPC, endothelial progenitor cell; EDD, end diastolic dimension; ESD, end systolic dimension; FS, fractional shortening; EF, ejection fraction.
* Indicates a significant difference between the EPC and control group (P < 0.05).
Figure 4 EPC treatment induced cardioprotection related proteins expression. Protein expression of platelet-derived growth factor (PDGF:
A), vascular endothelial growth factor (VEGF: B), fetal liver kinase-1 (Flk-1: C), fibroblast growth factor-17 (FGF-17: D), fibroblast growth factor
receptor-2 (FGFR-2: E), Tbx-18 (F), and β-Catenin (G) in heart tissue from rats 24 h after myocardial infarction. Rats were treated with endothelial
progenitor cells (EPCs) or were untreated (controls). Protein expression levels were determined by Western blot using heart tissue harvested from
non-infarct areas. Density units were normalized to the GAPDH loading control. *P < 0.05 compared with the EPC group. Data are presented as
mean ± standard deviation (n = 6 per group).
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of Akt may, in part, explain the enhanced cardiomyocyte
survival induced by Tβ4 in the present study, although
further experiments are required to confirm this.
Besides the ability of Tβ4 to mediate angiogenesis in a
long-term course [23], Tβ4 is integrally involved in
cell motility, migration and survival in the process of
cardiac morphogenesis. Results of our experiments
and others indicate that this protein can be reintroduced
in order to reduce post-infarction loss of cardiomyocytes
and may ultimately reduce the impact of prolonged
ischemic injury. However, because we did not use
Tβ4 and its blocker in chronically infarcted rats, we
cannot conclude that Tβ4 is involved in the chronic
phase of myocardial infarction.
PB-EPCs promote expression of proteins involved in
cardiac repair and regeneration
In this study, we observed that PB-EPCs increased or ac-
tivated the expression of proteins essential for cardiac
repair and regeneration. Considering the multifaceted
roles of VEGF, PDGF, β-Catenin, FGFR-2, FGF-17 and
Flk-1 in vessel formation [24-27], our findings suggest
that EPCs may promote cardiac regeneration after car-
diac injury, especially given that EPC transplantation sig-
nificantly increased the expression level of VEGF in the
infarct region. We detected significant changes in PDGF,
VEGF, and Flk-1 in the group receiving EPCs alone.
Upregulated expression of VEGF has previously been
found to be associated with a significant increase in the
number of both capillaries and arterioles after cardiac
injury [28,29]. Therefore, our finding is consistent with
that previously reported in a swine model, which showed
that EPCs increased neovascularization in the infarct
region border zone [30]. Those investigators described a
novel mechanism of cytoprotective gene expression that
can potentially extend cell survival at the genomic level,
and further suggested that a repetitive pattern of ischemia-
reperfusion may result in progressive cell protection and
survival. These results and ours suggest that activation and
increased expression of individual genes plays an important
role in cardioprotection.
PB-EPCs attenuate inflammation
In this study, we observed a decrease in post-ischemic
inflammation and endothelial apoptosis and significantly
enhanced cardiomyocyte survival after intramyocardial
injection of PB-EPCs transfected with scrambled SC
shRNA and of Tβ4 alone. Tβ4 alone significantly
reduced MPO activity, and similar inhibition in MPO
activity was observed in the EPCs + SC shRNA group,
resembling the effect of EPCs alone. In another study,
Tβ4-expressing cells found in cardiac valve precursors
known as “endocardial cushions” also expressed Akt as apossible interacting protein and part of the dominant
mechanism by which Tβ4 increases cell survival [22].
The Tβ4 protein was also found in the ventricular
septum, the compact layer of the trabecular region and
the outflow tract myocardium, indicating its presence in
migrating cells [22]. We believe that the effect of
injected Tβ4 to stimulate migration of myocardial cells
was also true in the present study.
Inflammation is now recognized as an important con-
tributing factor to atherosclerosis and heart disease [31].
A strong positive correlation also has been observed be-
tween the progression of coronary artery disease (CAD)
and circulating EPC levels, which are significantly lower
in patients with angiographic CAD progression [32]. In
fact, reduced levels of circulating EPCs may predict
cardiovascular disease progression. Ischemia-reperfusion
injury also is noted to have a marked inflammatory
response, including the release of cytotoxic substances,
oxygen-derived free radicals and proteases [17]. The Tβ4
protein is angiogenic, helping to form new vessels from
existing vasculature, and by this mechanism has been
shown to accelerate wound healing and reduce inflam-
mation [23]. Does it also have other antiinflammatory
effects? In a rat model of ischemia-reperfusion injury,
daidzein, an isoflavone found in soybeans, was adminis-
tered in vivo, attenuating myocardial damage by inhibiting
nuclear factor Kappa-b (NF-kB) activation, which in turn
suppressed activation of pro-inflammatory cytokines [17].
Infarct size and inflammation were reduced and cardiac
function was significantly improved in the daidzen-treated
rats; conversely, reperfusion after ischemia activated
NF-kB and increased levels of pro-inflammatory cyto-
kines. Another study showed that flavonoids protect
against ischemia-reperfusion injury by scavenging reactive
oxygen species (ROS), demonstrating protective efficacy
in cardiomyocytes [33]. However, it remains to be seen
whether antiinflammatory effects alone are sufficient to
reduce infarct size and improve cardiac function.
PB-EPCs improve post-infarction cardiac function
Transplantation of different cell populations, including
purified cardiomyocytes [34], human induced pluripo-
tent stem cells (iPS cells) [35], and EPCs [36] have all
shown improved cardiac contractile functioning. In the
present study, which used EPCs isolated from autolo-
gous peripheral blood to treat cardiomyocyte infarction,
random-blind ultrasonography with multiple measure-
ments of cardiac contraction was performed in all sur-
viving adult rats in the myocardial infarction model. At
4 weeks post-infarction, the LV fractional shortening in
the EPCs-treated group was larger than that of rats in
the control group. Two-dimensional echocardiographic
measurements of ventricular function also revealed that
the mean ejection fraction from the left ventricle in the
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ger than that of rats in the control group. ESDs and
EDDs in rats receiving EPC treatment were significantly
improved, suggesting that EPCs treatment resulted in
decreased cardiac dilation after myocardial infarction—a
sign of improved cardiac function. Reduced remodeling
of the heart after ischemic injury followed transplantation
of undifferentiated human iPS cells into immunosup-
pressed mice; although it resulted in tumor development,
the cells further differentiated into cardiac cells in vivo,
with a trend of declining EF compared to control rats with
infarction [37]. A study investigating post-infarction con-
tractile function of the heart via 2D echocardiography, sig-
nificantly impaired LV function was improved by 3% after
EPCs infected with stromal-cell derived factor-1α (SDF-
1α) were transplanted; SDF-1α promoted the proliferation
and migration of the EPCs into injured tissue [36]. EPCs
maintained their protection against progressive LV dilata-
tion and dysfunction compared to the MI control group.
The major mechanism appears to be paracrine pathways
of intramyocardial injection EPCs, resulting in the preven-
tion of apoptosis and enhanced neovascularization of is-
chemic myocardium [37]. Applying this understanding,
we can infer that the ability of PB-EPCs to prevent cell
death after coronary ligation probably leads to decreased
infarct size and improved ventricular function as observed
in rats in the present study.Conclusion
Results of this study suggest that PB-EPCs are able to
protect cardiomyocytes from ischemia-reperfusion or
infarction-induced damage in rat models via a Tβ4-
mediated mechanism. PB-EPCs may also provide protec-
tion through increased expression of proteins involved
in mediating vascular growth. Autologous peripheral-
blood-derived EPCs are readily available for efficient
therapeutic use without the concerns of graft rejection.
Findings of this study enhance the present understanding
of mechanisms underlying the cardioprotective effects of
EPCs in ischemia-reperfusion injury and myocardial
infarct.
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